Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/FCF ratio is N/A as of 2026-10-06T13:36:27.825Z.
Calculation as of: 2026-10-06T13:36:27.825Z.
Quote observation: 2026-10-06T13:30:37.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 5811ce025d9976e80ea69b9f8bae613fc78d61205a97c72640e2bc4d521a59ba
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/FCF RATIO
N/A
Market Cap
$53.53M
EV/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Eloxx Pharmaceuticals, Inc. (ELOX) | $53.11M | N/A | N/A | N/A | N/A |
| Dogwood Therapeutics, Inc. (DWTX)vs › | $52.80M | N/A | N/A | N/A | N/A |
| Connect Biopharma Holdings Limited (CNTB)vs › | $53.53M | N/A | N/A | N/A | N/A |
| ImageneBio Inc (IMA)vs › | $52.67M | N/A | N/A | N/A | N/A |
| Envoy Medical, Inc. (COCH)vs › | $51.78M | N/A | N/A | N/A | N/A |
| eXoZymes, Inc. (EXOZ)vs › | $51.23M | N/A | N/A | N/A | N/A |
| Apollomics, Inc. (APLM)vs › | $51.17M | N/A | N/A | N/A | N/A |
| INmune Bio, Inc. (INMB)vs › | $51.04M | N/A | N/A | N/A | N/A |
| biote Corp. (BTMD)vs › | $50.25M | 8.52x | 5.77x | 8.01x | 6.98x |
| Clene Inc. (CLNN)vs › | $49.84M | N/A | N/A | N/A | N/A |
EV/FCF
N/A
P/FCF
N/A
FCF Yield
N/A
Formula: EV/FCF = Enterprise Value / Free Cash Flow
EV/FCF vs P/FCF:
EV/FCF = Enterprise Value / Free Cash Flow (TTM)
Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
